Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma

NCT07301827 · tracked via the Priya Life Science China tracker

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase

Not applicable

Started

2025-06-01

Last updated

2025-12-24

Condition(s) studied

Renal Cell Carcinoma

Investigational drug(s) / intervention(s)

[68Ga]Ga-DOTA-CAIX peptide[68Ga]Ga-NOTA-CD70 antibody fragment[68Ga]Ga-PSMA

[68Ga]Ga-DOTA-CAIX peptide: To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed renal cell carcinoma with high CAIX expression and healthy volunteers, using specific positron imaging agents targeting CAIX (taking \[68Ga\]Ga-DOTA-CAIX peptide as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan. Healthy volunteers: Pharmacokinetic analysis will be performed to clarify the distribution and metabolism of the drug in the body and its safety.

[68Ga]Ga-NOTA-CD70 antibody fragment: To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed renal cell carcinoma with high CD70 expression and healthy volunteers, using specific positron imaging agents targeting CD70 (taking \[68Ga\]Ga-NOTA-CD70 antibody fragment as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan.

[68Ga]Ga-PSMA: To perform integrated PET/MR or PET/CT visualization of patients with clinically suspected or confirmed renal cell carcinoma with high PSMA expression and healthy volunteers, using specific positron imaging agents targeting PSMA (taking \[68Ga\]Ga-PSMA as an example), to achieve the following purposes: Patients with malignant tumors: for diagnosis and staging of diseases, comparing with the gold standard pathological diagnosis, evaluating diagnostic efficacy, clarifying the presence or absence of lesions, and determining the location and nature of lesions; comparing with \[18F\]FDG PET for accurate staging, evaluating the tumor load, and helping to determine the therapeutic plan.

Study summary

This study is a diagnostic study. This project aims to explore the clinical application value of PET imaging technologies targeting PSMA, CAIX, and CD70 in renal cell carcinoma. By utilizing PSMA-targeted PET radiopharmaceuticals (e.g., \[⁶⁸Ga\]Ga-PSMA), CAIX-targeted PET radiopharmaceuticals (e.g., \[⁶⁸Ga\]Ga-DOTA-CAIX), and CD70-targeted PET radiopharmaceuticals (e.g., \[⁶⁸Ga\]Ga-NOTA-CD70 antibody fragment) in patients with clinically suspected or confirmed renal cell carcinoma and healthy volunteers, we will investigate their diagnostic and therapeutic potential. \[⁶⁸Ga\]Ga-DOTA-CAIX peptide as an example), and a PET imaging agent targeting CD70 (\[⁶⁸Ga\]Ga-NOTA-CD70 antibody fragment as an example) in patients with clinically suspected or confirmed renal cell carcinoma and healthy volunteers. Integrated PET/MR or PET/CT imaging will be performed to aid in the diagnosis and staging of renal cell carcinoma, assess tumor burden and the expression levels of PSMA, CAIX, and CD70, and assist in determining treatment strategies. Concurrently, preliminary pharmacokinetic analysis of the novel CAIX-targeting molecular probe will be conducted in healthy volunteers to elucidate its metabolic patterns and adverse reactions in vivo.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Accepted

Inclusion Criteria: Tumor subjects: 1. The subject or his/her legal representative is able to sign the informed consent form signed and dated; 2. Promise to abide by the research procedures and cooperate with the implementation of the whole process of research; 3. Adult subjects (aged 18 years or above), male or female; 4. Patients with clinically suspected or confirmed renal cell carcinoma (supporting evidence includes serum-related tumor markers, ultrasound, CT, MRI and other imaging data and histopathological examinations, etc.), and are in good general condition; 5. Conform to specific laboratory test results; 6. Contraception for at least one month before screening for females in the childbearing period, and commitment to use contraception throughout the study period and continue until the specified time after the end of the study; 7. Other set selection criteria. Healthy Subjects: 1. Fully understand and voluntarily sign the informed consent form; 2. Male or female, age 18-70 years old; 3. Male weight \>=50.0kg, female weight \>=45.0kg; Body mass index (BMI) within the range of 19.0\~26.0kg/m\^2 (including the cut-off value); 4. No history of chronic or serious diseases such as cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immunologic, psychiatric, neuromuscular, gastrointestinal system, etc., within three years, and in good general health; 5. There is no abnormality in vital signs examination and physical examination; 6. Have no fertility plan during the trial and within 6 months after the end of the trial and voluntarily take effective contraceptive measures and have no sperm and egg donation plans; 7. Able to communicate well with the investigator, and understand and comply with the requirements of the study. Exclusion Criteria: Tumor subjects: 1. Those who are unable to complete PET/MR or PET/CT examination (including inability to lie flat, claustrophobia, radiophobia, etc.); 2. Patients with known hypersensitivity to targeted PSMA, CAIX or CD70 PET imaging agents or synthetic excipients; The fasting blood glucose level before injection of \[18F\]FDG exceeded 11.0 mmol/L; 3. Patients who are pregnant or lactating; 4. Those who have other factors that are not suitable for participating in this test. Healthy Subjects: 1. Any serious or unstable medical condition; Those who have acute illness before the study; Previous or existing malignancy; 2. Pregnant and lactating women; 3. Those who have undergone surgery within 6 months before the trial, which is judged by the investigator to affect absorption, distribution, metabolism, and excretion; 4. Those who have used any drugs (including prescription drugs, over-the-counter drugs, and Chinese herbal medicines) within 2 weeks before the trial; 5. Participation in other research studies involving radioactive materials (within the past 12 months); 6. Any other factors that affect the results of the study.

Primary outcome measure(s)

Visual and standardized uptake values assessment of lesions and biodistribution — 1 year
At least two experienced nuclear medicine physicians will conduct a visual analysis using consensus reading. The standardized uptake value (SUV) of tumor and organs will be measured after a semiquantitative analysis is conducted for each case. The SUV ranges from 0 to infinity, and a higher score means a higher uptake of nuclear probe by the tumor, which implies a greater threat of the tumor being malignant or higher stage.

Trial sites (1)

Facility	City	Region	Status
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei	Recruiting

More Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials in China

Clinical Trial of the Safety and Efficacy of Peripheral Nerve Stimulation in the Treatment of Peripheral Neuropathic Pain. Recruiting

Clinical Effectiveness of CEM in Diagnosis of Additional Findings at Preoperative Breast Magnetic Resonance Imaging Starting soon

Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM Recruiting

Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE Recruiting

Dalpiciclib Combined With Aromatase Inhibitors and Olmesartan as the First-line Treatment for HR+/HER2- Advanced Breast Cancer Recruiting

Other trials for the same condition

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors Active, not recruiting

A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). Active, not recruiting

The Cold Ischemia Robot-assisted Partial Nephrectomy Recruiting

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) Active, not recruiting

A Study of Multimodal Radiotherapy for Renal Cell Carcinoma Progressed After Prior Immunotherapy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07301827 on ClinicalTrials.gov ↗ ← All trials in China